Sustained CA19-9 Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer Predicts Progression and Survival

Oncologist - United States
doi 10.1634/theoncologist.2019-0878
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

Erratum To: Extended Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer Demonstrates Promising Postoperative Outcomes and Survival

Annals of Surgical Oncology
OncologySurgery
2014English

A Pilot Study- Neoadjuvant Chemotherapy With Gemcitabine and S1 in Patients With Resectable and Borderline Resectable Pancreatic Cancer

Journal of Carcinogenesis & Mutagenesis
2013English

Target Capture RNA Sequencing as a Method of Predicting Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer: A Multi-Institutional Study

HPB
HepatologyGastroenterology
2019English

Preoperative Nomogram to Predict Survival for Patients With Resectable and Borderline Resectable Pancreatic Cancer

HPB
HepatologyGastroenterology
2017English

Complete Pathological Response Following Neoadjuvant FOLFIRINOX in Borderline Resectable Pancreatic Cancer - A Case Report and Review

BMC Cancer
Cancer ResearchOncologyGenetics
2016English

Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials

Journal of Clinical Medicine
2020English

Operative Outcomes Following Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy (Sbrt) for Borderline Resectable and Locally Advanced Pancreatic Cancer

HPB
HepatologyGastroenterology
2019English

Meta-Analysis Comparing Upfront Surgery With Neoadjuvant Treatment in Patients With Resectable or Borderline Resectable Pancreatic Cancer

British Journal of Surgery
Surgery
2018English

Management of Borderline Resectable Pancreatic Cancer

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy